AptarGroup Acquires Manufacturing Capabilities from Mod3 Pharma

AptarGroup, a company that designs and manufactures drug and consumer product dosing, dispensing, and protection technologies, has acquired the manufacturing capabilities of Mod3 Pharma from SWK. The acquisition expands AptarGroup's offerings in the pharmaceutical market and strengthens its position in the industry.

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing, and protection technologies, has acquired the manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. The acquisition, announced on July 15, 2025, enhances AptarGroup's offerings in the pharmaceutical market and strengthens its position in the industry.

The acquisition includes the clinical trial materials manufacturing capabilities of Mod3 Pharma, which specializes in formulation, fill, and finish services for Phase 1 and 2 clinical trials. This strategic move will allow AptarGroup to offer its customers a more comprehensive range of services, including cGMP (Current Good Manufacturing Practices) clinical trial material supply services [1].

The new capabilities will be operated from an FDA-inspected, state-of-the-art facility in Boonton, New Jersey. The facility includes cGMP cleanrooms, high-potency Active Pharmaceutical Ingredient (API) suites, biologics capabilities, and advanced fill-finish technologies, fully aligned with AptarGroup's drug delivery solutions portfolio [1].

Gael Touya, President of Aptar Pharma, commented, "Our vision at Aptar Pharma is clear: From formulation to patient. By integrating Phase 1 and 2 clinical manufacturing capabilities, we’re not just expanding our technical footprint – we’re deepening our commitment to customers seeking a seamless and accelerated path to market. This move reinforces our position as a trusted partner from molecule to delivery, and ultimately, to the patient" [1].

Sai Shankar, President of M&A, Strategy, Business Development, Marketing, and Drug Services, added, "We’re expanding our niche services to help customers move faster in areas of unmet need, and without duplicating the strengths of our trusted partners. This strategic expansion of our services builds on our legacy in drug dosing and dispensing systems by integrating deeper expertise as a drug delivery innovator, as well as product development and formulation, allowing us to offer more specialized and holistic support to our customers" [1].

The acquisition also accelerates the adoption of new drug delivery technologies, initially focusing on orally inhaled nasal drug products (OINDPs), with potential expansion into dermal, ophthalmic, injectable, and secondary packaging solutions using AptarGroup’s Active Material Science Solutions [1].

Dr. Paul Shields, CEO of Mod3 Pharma, remarked, "We are delighted to become part of the Aptar family. This acquisition reflects our shared commitment of accelerating the development of innovative therapies and bringing them to patients faster" [1].

This strategic move is expected to bolster AptarGroup's market position and support its growth in the pharmaceutical sector. The acquisition aligns with AptarGroup's long-term strategy to expand its service offerings and strengthen its position as a trusted partner in drug delivery and active material science solutions.

References:
[1] https://aptar.com/news-events/aptar-pharma-clinical-trial-materials-manufacturing-capabilities-acquisition/
[2] https://www.morningstar.com/news/business-wire/20250715970521/aptar-pharma-bolsters-clinical-trial-capabilities-with-strategic-materials-manufacturing-acquisition